Current trends in the management of chronic myelogenous leukemia

Annals of Hematology

Volumn 79, Issue 7, 2000, Pages 345-354

  Hehlmann, R ^a   Hochhaus, A ^a   Berger, U ^a   Reiter, A ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Allograft; Autograft; Bone marrow transplantation; Chronic myelogenous leukemia; Management

Indexed keywords

ALPHA INTERFERON; BCR ABL PROTEIN; BUSULFAN; CYTARABINE; CYTARABINE 5' STEARYLPHOSPHATE; HOMOHARRINGTONINE; IMATINIB; PROTEIN TYROSINE KINASE INHIBITOR; UNCLASSIFIED DRUG;

ALGORITHM; ALLOGENIC BONE MARROW TRANSPLANTATION; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; DIAGNOSTIC APPROACH ROUTE; DISEASE COURSE; EVIDENCE BASED MEDICINE; FLUORESCENCE IN SITU HYBRIDIZATION; HUMAN; LYMPHOCYTE; PATIENT MONITORING; PHILADELPHIA 1 CHROMOSOME; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; SOUTHERN BLOTTING; STEM CELL TRANSPLANTATION; TREATMENT OUTCOME; TREATMENT PLANNING;

BONE MARROW TRANSPLANTATION; HUMANS; INTERFERONS; LEUKEMIA, MYELOID, CHRONIC;

EID: 0033910624     PISSN: 09395555     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002770000167     Document Type: Review

References (72)

1. Silver RT, Woolf SH, Hehlmann R, Appelbaum FA, Anderson J, Bennett C, Goldman JM, Guilhot F, Kantarjian HM, Lichtin AE, Talpaz M, Tura S (1999) Review: an evidence-based analysis of the effect of busulfan, hydroxyurea, interferon, and allogeneic bone marrow transplantation in treating the chronic phase of chronic myeloid leukemia: developed for the American Society of Hematology. Blood 94:1517-1536
2. Hehlmann R, Heimpel H, Hasford J, Kolb HJ, Pralle H, Hossfeld DK, Queisser W, Löffler H, Hochhaus A, Heinze B, Georgii A, Bartram CR, Griesshammer M, Bergmann L, Essers U, Falge C, Queisser U, Meyer P, Schmitz N, Eimermacher H, Walther F, Fett W, Kleeberg UR, Käbisch A, Nerl C, Zimmermann R, Meuret G, Tichelli A, Kanz L, Tigges FJ, Schmid L, Brockhaus W, Tobler A, Reiter A, Perker M, Emmerich B, Verpoort K, Zankovich R, Von Wussow P, Prümmer O, Thiele J, Buhr T, Carbonell F, Ansari H, and the German CML Study Group (1994) Randomized comparison of interferon-α with busulfan and hydroxyurea in chronic myelogenous leukemia. Blood 84:4064-4077
3. The Italian Cooperative Study Group on Chronic Myeloid Leukemia (1994) Interferon α-2a as compared with conventional chemotherapy for the treatment of chronic myeloid leukemia. N Engl J Med 330:820-825
4. Allan NC, Richards SM, Shepherd PC (1995) UK Medical Research Council randomised, mullicentre trial of interferon-α n1 for chronic myeloid leukaemia: improved survival irrespective of cytogenetic response. The UK Medical Research Council's Working Parties for Therapeutic Trials in Adult Leukaemia. Lancet 345:1392-1397
5. Ohnishi K, Ohno R, Tomonaga M, Kamada N, Onozawa K, Kuramoto A, Dohy H, Mizoguchi H, Miyawaki S, Tsubaki K, et al. (1995) A randomized trial comparing interferon-α with busulfan for newly diagnosed chronic myelogenous leukemia in chronic phase. Blood 86:906-916
6. Chronic Myeloid Leukemia Trialist's Collaborative Group (1997) Interferon α versus chemotherapy for chronic myeloid leukemia: a meta-analysis of seven randomized trials. J Natl Cancer Inst 89:1616-1620
7. The Benelux CML Study Group. (1998) Randomized study on hydroxyurea alone versus hydroxyurea combined with low-dose interferon-α2b for chronic myeloid leukemia. Blood 91:2713-2721
8. Hehlmann R, Heimpel H, Hossfeld DK, Hasford J, Kolb HJ, Löffler H, Pralle H, Queisser W, Hochhaus A, Tichelli A, Fett W, Schmitz N, Reiter A, Griesshammer M, Pfeifer W, Bäumler M, Kamp T, Tobler A, Eimermacher H, Kuse R, Berger U, Ansari H, and the German CML Study Group (1996) Randomized study of the combination of hydroxyurea and interferon α versus hydroxyurea monotherapy during the chronic phase of chronic myelogenous leukemia (CML Study II). Bone Marrow Transplant 17[suppl 3]:S21-S24
9. Guilhot F, Chastang C, Michallet M, Guerci A, Harousseau JL, Maloisel F, Bouabdallah R, Guyotat D, Cheron N, Nicolini F, Abgrall JF, Tanzer J (1997) Interferon α2b (IFN) combined with cytarabine versus interferon alone in chronic myelogenous leukemia. N Engl J Med 337:223-229
10. The Italian Cooperative Study Group on Chronic Myeloid Leukemia (1998) Long-term follow-up of the Italian trial of interferon-a versus conventional chemotherapy in chronic myeloid leukemia. Blood 92:1541-1548
11. Hasford J, Baccarani M, Hehlmann R, Ansari H, Tura S, Zuffa E (1996) Interferon-α and hydroxyurea in early chronic myeloid leukemia: a comparative analysis of the Italian and German chronic myeloid leukemia trials with interteron-α Blood 88:5384-5391
12. Sokal JE, Cox EB, Baccarani M, Tura S, Gomez GA, Robertson JE, Tso CY, Braun TJ, Clarkson BD, Cervantes F, Rozman C (1984) Prognostic discrimination in "good-risk" chronic granulocytic leukemia. Blood 63:789-799
13. Hasford J, Pfirrmann M, Hehlmann R, Allan NC, Baccarani M, Kluin-Nelemans J, Alimena G, Steegmann JL, Ansari H (1998) A new prognostic score for the survival of patients with chronic myeloid leukemia treated with interferon α. J Natl Cancer Inst 90:850-858
14. Alimena G, Morra E, Lazzarino M, Liberati AM, Montefusco E, Inverardi D, Bernasconi P, Mancini M, Donti E, Grignani F, et al. (1988) Interferon α-2b as therapy for Ph′-positive chronic myelogenous leukemia: a study of 82 patients treated with intermittent or daily administration. Blood 72:642-647
15. Montastruc M, Mahon FX, Faberes C, Marit G, Bilhou Nabera C, Cony Makhoul P, Puntous M, Pigneux A, Boiron JM, Bernard P, Salmi R, Broustet A, Reiffers J (1995) Response to recombinant interferon α in patients with chronic myelogenous leukemia in a single center: results and analysis of predictive factors. Leukemia 9:1997-2002
16. Tura S (1998) Cytarabine increases karyotypic response in α-IFN treated chronic myeloid leukemia patients: results of a national prospective randomized trial. Blood 92:317a
17. Hehlmann R, Heimpel H (1996) Current aspects of drug therapy in Philadelphia-positive CML: Correlation of tumor burden with survival. Leuk Lyinphoma 22:161-167
18. Zhang MJ, Baccarani M, Gale RP, McGlave PB, Atkinson K, Champlin RE, Dicke KA, Giralt S, Gluckman E, Goldman JM, Klein JP, Herzig RH, Masaoka T, O'Reilly RJ, Rozman C, Rowlings PA, Sobocinski KA, Speck B, Zwaan FE, Horowitz MM (1997) Survival of patients with chronic myelogenous leukaemia relapsing after bone marrow transplantation: comparison with patients receiving conventional chemotherapy. Br J Haematol 99:23-29
19. McGlave PB, De Fabritiis P, Deisseroth A, Goldman J, Barnett M, Reiffers J, Simonsson B, Carella A, Aeppli D (1994) Autologous transplants for chronic myelogenous leukaemia: results from eight transplant groups. Lancet 343:1486-1488
20. Carella AM, Frassoni F (1996) Ice, mini-ice or high-dose hydroxyurea to mobilize Philadelphia (Ph1)-negative PBPC in chronic myelogenous leukaemia. Br J Haematol 95:213-214
21. Goldman JM (1996) Autografting for CML - overview and perspectives. Bone Marrow Transplant 17[suppl 3]:S71-S74
22. Cunningham I, Gee T, Dowling M, Chaganti R, Bailey R, Hopfan S, Bowden L, Turnbull A, Knapper W, Clarkson B (1979) Results of treatment of Ph′+ chronic myelogenous leukemia with an intensive treatment regimen (L-5 protocol). Blood 53:375-395
23. 1-positive chronic myeloid leukaemia with combination chemotherapy. Lancet 1:1370-1372
24. Kantarjian HM, Talpaz M, Kurzrock R, Keating MJ, McCredie KB, Gutterman J, Freireich EJ (1987) Intensive combination chemotherapy and interferons in the management of chronic myelogenous leukemia. Acta Haematol 78:70-74
25. Kolitz JE, Kempin SJ, Schluger A, Wong GY, Berman E, Jhanwar S, Arlin ZA, Gee T, Clarkson BD (1992) A phase II pilot trial of high-dose hydroxyurea in chronic myelogenous leukemia. Semin Oncol 19[suppl 9]:27-33
26. Hehlmann R, Heimpel H, Hasford J, Kolb HJ, Pralle H, Hossfeld DK, Queisser W, Löffler H, Heinze B, Georgii A, Von Wussow P, Bartram C, Griesshammer M, Bergmann L, Essers U, Falge C, Hochhaus A, Queisser U, Sick C, Meyer P, Schmitz N, Verpoort K, Eimermacher H, Walther F, Westerhausen M, Kleeberg UR, Heilein A, Käbisch A, Barz C, Zimmermann R, Meuret G, Tichelli A, Berdel WE, Kanz L, Anger B, Tigges FJ, Schmid L, Brockhaus W, Zankovich R, Schläfer U, Weissenfels I, Mainzer K, Tobler A, Perker M, Hohnloser J, Messerer D, Thiele J, Buhr T, Ansari H, and the German CML Study Group (1993) Randomized comparison of busulfan and hydroxyurea in chronic myelogenous leukemia: prolongation of survival by hydroxyurea. Blood 82:398-407
27. Shepherd PCA, Richards SM, Allan NC (1996) Progress with interferon in CML - results of the MRC UK CML III Study. Bone Marrow Transplant 17[suppl 3]:S15-S18
28. Hehlmann R, Hochhaus A (1999) Changing nature of conventional therapy in chronic myelogenous leukemia. In: Talpaz M, Kantarjian HM (eds) Medical management of chronic myelogenous leukemia. Marcel Dekker, New York, pp 113-139
29. Talpaz M, Cortes J, O'Brien S, Keating M, Giles F, Rose E, Rybak ME, Kantarjian H (1998) Phase I study of polyethylene glycol (PEG) interferon α-2b (intron-A) in CML patients. Blood 92:251a
30. O'Brien S, Kantarjian H, Keating M, Beran M, Koller C, Robertson LE, Hester J, Rios MB, Andreeff M, Talpaz M (1995) Homoharringtonine therapy induces responses in patients with chronic myelogenous leukemia in late chronic phase. Blood 86:3322-3326
31. O'Brien S, Kantarjian H, Koller C, Feldman E, Beran M, Andreeff M, Giralt S, Cheson B, Keating M, Freireich E, Rios MB, Talpaz M (1999) Sequential homoharringtonine and interferon-α in the treatment of early chronic phase chronic myelogenous leukemia. Blood 93:4149-4153
32. Druker BJ, Tamura S, Buchdunger E, Ohno S, Segal GM, Fanning S, Zimmermann J, Lydon NB (1996) Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med 2:561-566
33. Druker BJ, Talpaz M, Resta D, Peng B, Buchdunger E, Ford J, Sawyers CL (1999) Clinical efficacy and safety of an abl specific tyrosine kinase inhibitor as targeted therapy for chronic myelogenous leukemia. Blood 94:368a
34. Carroll M, Ohno-Jones S, Tamura S, Buchdunger E, Zimmermann J, Lydon NB, Gilliland DG, Druker BJ (1997) CGP57148, a tyrosine kinase inhibitor, inhibits the growth of cells expressing BCR-ABL, TEL-ABL, and TEL-PDGFR fusion proteins. Blood 90:4947-4952
35. Kantarjian HM, Smith TL, O'Brien S, Beran M, Pierce S, Talpaz M, and the Leukemia Service (1995) Prolonged survival in chronic myelogenous leukemia after cytogenetic response to interferon-α therapy. Ann Intern Med 122:254-261
36. Clarkson B, Strife A (1993) Linkage of proliferative and maturational abnormalities in chronic myelogenous leukemia and relevance to treatment. Leukemia 7:1683-1721
37. Morley A (1998) Quantifying leukemia. N Engl J Med 339:627-629
38. Hochhaus A, Lin F, Reiter A, Skladny H, Mason PJ, Van Rhee F, Shepherd PCA, Allan NC, Hehlmann R, Goldman JM, Cross NCP (1996) Quantification of residual disease in chronic myelogenous leukemia patients on interferon-α therapy by competitive polymerase chain reaction. Blood 87:1549-1555
39. Hochhaus A, Reiter A, Saussele S, Reichert A, Emig M, Kaeda J, Schultheis B, Berger U, Shepherd PCA, Allan NC, Hehlmann R, Goldman JM, Cross NCP, for the German CML Study Group and the UK MRC CML Study Group. (2000) Molecular heterogeneity in complete cytogenetic responders after interferon α therapy for chronic myelogenous leukemia: low levels of minimal residual disease are associated with continuing remission. Blood 95:62-66
40. Reiter A, Marley SB, Hochhaus A, Sohal J, Raanani P, Hehlmann R, Gordon MY, Goldman JM, Cross NCP (1998) BCR-ABL-positive progenitors in chronic myeloid leukaemia patients in complete cytogenetic remission after treatment with interferon-α. Br J Haematol 102:1271-1278
41. Kurzrock R, Estrov Z, Kantarjian H, Talpaz M (1998) Conversion of interferon-induced, long-term cytogenetic remissions in chronic myelogenous leukemia to polymerase chain reaction negativity. J Clin Oncol 16:1526-1531
42. Emig M, Saussele S, Wittor H, Weisser A, Reiter A, Willer A, Berger U, Hehlmann R, Cross NCP, Hochhaus A (1999) Accurate and rapid analysis of residual disease in patients with CML using specific fluorescent hybridization probes for real time quantitative RT-PCR. Leukemia 13:1825-1832
43. Biernaux C, Loos M, Sels A, Huez G, Stryckmans P (1995) Detection of major bcr-abl gene expression at a very low level in blood cells of some healthy individuals. Blood 88:3118-3122
44. Bose S, Deininger M, Gora-Tybor J, Goldman JM, Melo JV (1998) The presence of typical and atypical BCR-ABL fusion genes in leukocytes of normal individuals: biologic significance and implications for the assessment of minimal residual disease. Blood 92:3362-3367
45. Melo JV (1996) The molecular biology of chronic myeloid leukaemia. Leukemia 10:751-756
46. Hehlmann R (1998) A chance of cure for every patient with CML? N Engl J Med 338:980-982
47. Goldman JM, Szydlo R, Horowitz MM, Gale RP, Ash RC, Atkinson K, Dicke KA, Gluckman E, Herzig RH, Marmont A, et al. (1993) Choice of pretransplant treatment and timing of transplants for chronic myelogenous leukemia in chronic phase. Blood 82:2235-2238
48. Van Rhee F, Szydlo RM, Hermans J, Devergie A, Frassoni F, Arcese W, De Witte T, Kolb HJ, Niederwieser D, Jacobsen N, Gahrton G, Bandini G, Carreras E, Bacigalupo A, Michallet M, Ruutu T, Reiffers J, Goldman JM, Apperley J, Gratwohl A, Apperley JF, Labopin M, Madrigal A, Prentice HG, Jouet JP, Hertenstein B, Evensen SA, Ljungman P, Nagler A, Clark RE (1997) Long-term results after allogeneic bone marrow transplantation for chronic myelogenous leukemia in chronic phase: a report from the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation European results of matched unrelated donor bone marrow transplantation for chronic myeloid leukemia. Impact of HLA class II matching. Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant 20:11-19
49. Devergie A, Reiffers J, Vernant JP, Herve P, Guyotat D, Maraninchi D, Rio B, Michallet M, Jouet JP, Milpied N, Leblond V, Pico J, Attal M, Belanger C, Bordigoni P, Leporrier M, Ifrah N, Gratecos N, Bergerat JP, Legros M, Frappaz D, Gluckman E (1990) Long-term follow-up after bone marrow transplantation for chronic myelogenous leukemia: factors associated with relapse. Bone Marrow Transplant 5:379
50. Clift RA, Buckner CD, Thomas ED, Bensinger WI, Bowden R, Bryant E, Deeg HJ, Doney KC, Fisher LD, Hansen JA, et al. (1994) Marrow transplantation for chronic myeloid leukemia: a randomized study comparing cyclophosphamide and total body irradiation with busulfan and cyclophosphamide. Blood 84:2036-2043
51. Beelen DW, Graeven U, Elmaagacli AH, Niederle N, Kloke O, Opalka B, Schaefer UW (1995) Prolonged administration of interferon-α in patients with chronic-phase Philadelphia chromosome-positive chronic myelogenous leukemia before allogeneic bone marrow transplantation may adversely affect transplant outcome. Blood 85:2981-2990
52. Gale RP, Hehlmann R, Zhang M-J, Hasford J, Goldman JM, Heimpel H, Hochhaus A, Klein JP, Kolb HJ, McGlave PB, Passweg JR, Rowlings PA, Sobocinski KA, Horowitz MM, and the German CML Study Group (1998) Survival with bone marrow transplantation versus hydroxyurea or interferon for chronic myelogenous leukemia. Blood 91:1810-1819
53. Gratwohl A, Hermans J, Goldman JM, Frassoni F, Devergie A, Carreras E, Kolb HJ, Gahrton G, Arcese W, Vernant JP, Ruutu T, De Witte T, Van Rhee F, Apperley J, for the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). (1998) Risk assessment for patients with chronic myeloid leukemia before allogeneic blood or marrow transplantation. Lancet 352:1087-1092
54. Hansen JA, Gooley TA, Martin PJ, Appelbaum F, Chauncey TR, Clift RA, Petersdorf EW, Radich J, Sanders JE, Storb RF, Sullivan KM, Anasetti C (1998) Bone-marrow transplants from unrelated donors for patients with chronic myeloid leukemia. N Engl J Med 338:962-968
55. Hehlmann R, Hochhaus A, Kolb HJ, Hasford J, Gratwohl A, Heimpel H, Siegert W, Finke J, Ehninger G, Holler E, Berger U, Pfirrmann M, Muth A, Zander A, Fauser AA, Heyll A, Nerl C, Hossfeld DK, Löffler H, Pralle H, Queisser W, Tobler A, for the German CML-Study Group and the SAKK. (1999) Interferon α before allogeneic bone marrow transplantation in chronic myelogenous leukemia does not affect outcome adversely, provided it is discontinued at least 90 days before the procedure. Blood 94:3668-3677
56. Schmitz N, Bacigalupo A, Hasenclever D, Nagler A, Gluckman E, Clark P, Bourquelot P, Greinix H, Frickhofen N, Ringden O, Zander A, Apperley JF, Gorin C, Borkett K, Schwab G, Goebel M, Russel NH, Gratwohl A (1998) Allogeneic bone marrow transplantation vs filgrastim-mobilised peripheral blood progenitor cell transplantation in patients with early leukaemia: first results of a randomised multicentre trial of the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant 21:995-1003
57. + peripheral blood stem cells in patients with advanced hematologic malignancy. Bone Marrow Transplant 17:S38-S39
58. Körbling M, Przepiorka D, Huh YO, Engel H, Van Besien K, Giralt S, Andersson B, Kleine HD, Seong D, Deisseroth AB, Andreeff M, Champlin R (1995) Allogeneic blood stem cell transplantation for refractory leukemia and lymphoma: potential advantage of blood over marrow allografts. Blood 85:1659-1665
59. Elmaaglacli AH, Beelen DW, Opalka B, Seeber S, Schaefer UW (1999) The risk of residual molecular and cytogenetic disease in patients with Philadelphia-chromosome positive first chronic phase chronic myelogenous leukemia is reduced after transplantation of allogeneic peripheral blood stem cells compared with bone marrow. Blood 94:384-389
60. Ringden O, Remberger M, Runde V, Bornhäuser M, Blau IW, Basara N, Hölig K, Beelen DW, Hägglund H, Basu O, Ehninger G, Fauser AA (1999) Peripheral blood stem cell transplantation from unrelated donors: a comparison with marrow transplantation. Blood 94:455-464
61. Cross NCP, Feng L, Chase A, Bungey J, Hughes TP, Goldman JM (1993) Competitive polymerase chain reaction to estimate the number of BCR-ABL transcripts in chronic myeloid leukemia patients after bone marrow transplantation. Blood 82:1929-1936
62. Appelbaum FR, Clift R, Radich J, Anasetti C, Buckner CD (1995) Bone marrow transplantation for chronic myelogenous leukemia. Semin Oncol 22:405-411
63. Morton AJ, Gooley T, Hansen JA, Appelbaum FR, Bruemmer B, Bjerke JW, Clift R, Martin PJ, Petersdorf EW, Sanders JE, Storb R, Sullivan KM, Woolfrey A, Anasetti C (1998) Association between pretransplant interferon-a and outcome after unrelated donor marrow transplantation for chronic myelogenous leukemia in chronic phase. Blood 92:394-401
64. Holler E, Schleuning M, Ledderose G, Mittermüller H, Wilmanns W, Kolb HJ (1996) IFN α prior to allogeneic BMT in patients with chronic myelogenous leukemia. Ann Hematol 73:A96
65. Raanani P, Dazzi F, Sohal J, Szydlo R, Van Rhee F, Reiter A, Lin F, Goldman JM, Cross NCP (1997) The rate and kinetics of molecular response to donor leucocyte transfusions in chronic myeloid leukaemia patients treated for relapse after allogeneic bone marrow transplantation. Br J Haematol 99:945-950
66. Kolb HJ, Schattenberg A, Goldman JM, Hertenstein B, Jacobsen N, Arcese W, Ljungman P, Ferrant A, Verdonck L, Niederwieser D, Van Rhee F, Mittermueller J, De Witte T, Holler E, Ansari H, for the European Group for Blood and Marrow Transplantation Working Party Chronic Leukemia (1995) Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. European Group for Blood and Marrow Transplantation Working Party Chronic Leukemia. Blood 86:2041-2050
67. Steegmann JL, Casado LF, Tomas JF, Sanz-Rodriguez C, Granados E, De la Camara R, Alegre A, Vazquez L, Ferro MT, Figuera A, Arranz R, Fernandez-Rananda JM (1999) Interferon α for chronic myeloid leukemia relapsing after allogeneic bone marrow transplantation. Bone Marrow Transplant 23:483-488
68. Kolb HJ, Mittermuller J, Clemm C, Holler E, Ledderose G, Brehm G, Heim M, Wilmanns W (1990) Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients. Blood 76: 2462-2465
69. Giralt S, Estey E, Albitar M, Van Besien K, Rondon G, Anderlini P, O'Brien S, Khouri I, Gajewski J, Mehra R, Claxton D, Andersson B, Beran M, Prezpiorka D, Koller C, Kornblau S, Körbling M, Keating M, Kantarjian H, Champlin R (1997) Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: harnessing graft-versus-leukemia without myeloablative therapy. Blood 89:4531-4536
70. Slavin S, Nagler A, Naparstek E, Kapelushnik Y, Aker M, Cividalli G, Varadi G, Kirschbaum M, Ackerstein A, Samuel S, Amar A, Brautbar C, Ben-Tal O, Eldor A, Or R (1998) Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood 91:756-763
71. Carella AM, Podesta M, Frassoni F, Raffo MR, Pollicardo N, Pungolino E, Vimercati R, Sessarego M, Parodi C, Rabitti C, et al. (1993) Collection of "normal" blood repopulating cells during early hemopoietic recovery after intensive conventional chemotherapy in chronic myelogenous leukemia. Bone Marrow Transplant 12:267-271
72. Carella AM, Cunningham I, Lerma E, Dejana A, Benvenuto F, Podestà M, Celesti L, Chimirri F, Abate M, Vassallo F, Figari O, Parodi C, Sessarego M, Valbonesi M, Carlier P, Prencipe E, Gatti AM, Van den Berg D, Hoffman R, Frassoni F (1997) Mobilization and transplantation of Philadelphia-negative peripheral-blood progenitor cells early in chronic myelogenous leukemia. J Clin Oncol 15:1575-1582